| Primary |
| Drug Use For Unknown Indication |
82.6% |
| Atypical Mycobacterium Pericarditis |
5.8% |
| Hiv Infection |
4.3% |
| Pain |
2.9% |
| Breast Cancer |
1.4% |
| Parenteral Nutrition |
1.4% |
| Vitamin Supplementation |
1.4% |
|
| Drug Intolerance |
25.0% |
| Mania |
25.0% |
| Renal Failure |
25.0% |
| Respiratory Disorder |
25.0% |
|
| Secondary |
| Product Used For Unknown Indication |
14.9% |
| Supplementation Therapy |
14.9% |
| Pancreatitis |
8.3% |
| Sedation |
7.5% |
| Short-bowel Syndrome |
5.3% |
| Hiv Infection |
4.8% |
| Hypertension |
4.8% |
| Constipation |
4.4% |
| Thrombosis Prophylaxis |
4.4% |
| Pain |
3.9% |
| Wegener's Granulomatosis |
3.5% |
| Nausea |
3.1% |
| Prophylaxis |
3.1% |
| Endotracheal Intubation |
2.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.6% |
| Sepsis |
2.6% |
| Withdrawal Syndrome |
2.6% |
| Alcohol Withdrawal Syndrome |
2.2% |
| Hyperglycaemia |
2.2% |
| Pyrexia |
2.2% |
|
| Injection Site Induration |
15.4% |
| Death |
11.5% |
| Stevens-johnson Syndrome |
11.5% |
| Toxic Epidermal Necrolysis |
11.5% |
| Inflammation |
7.7% |
| Local Swelling |
7.7% |
| Convulsion |
3.8% |
| Dysgeusia |
3.8% |
| Encephalitic Infection |
3.8% |
| Erythema |
3.8% |
| Intracranial Pressure Increased |
3.8% |
| Skin Oedema |
3.8% |
| Tremor |
3.8% |
| Unresponsive To Stimuli |
3.8% |
| Venous Occlusion |
3.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.4% |
| Product Used For Unknown Indication |
16.2% |
| Unevaluable Event |
10.6% |
| Sarcoma |
7.4% |
| Sepsis |
5.6% |
| Hypertension |
4.7% |
| Pain |
4.5% |
| Prophylaxis |
3.4% |
| Anaemia |
2.7% |
| Hyperparathyroidism Secondary |
2.7% |
| Parenteral Nutrition |
2.7% |
| Thrombosis Prophylaxis |
2.7% |
| Acute Myeloid Leukaemia |
2.6% |
| Renal Failure Chronic |
2.5% |
| Head And Neck Cancer |
2.4% |
| Infection |
2.3% |
| Weight Decreased |
2.3% |
| Crohn's Disease |
2.2% |
| Acute Leukaemia |
1.9% |
| Antibiotic Therapy |
1.9% |
|
| Toxic Epidermal Necrolysis |
11.0% |
| Thrombocytopenia |
9.9% |
| Rhabdomyolysis |
7.7% |
| Toxic Skin Eruption |
7.7% |
| Septic Shock |
5.5% |
| Hypoxia |
4.4% |
| Rash Pustular |
4.4% |
| Rectal Haemorrhage |
4.4% |
| Renal Failure Acute |
4.4% |
| Respiratory Failure |
4.4% |
| Staphylococcal Bacteraemia |
4.4% |
| Vomiting |
4.4% |
| Wound Dehiscence |
4.4% |
| Activated Partial Thromboplastin Time Prolonged |
3.3% |
| Cardio-respiratory Arrest |
3.3% |
| Cytolytic Hepatitis |
3.3% |
| Peripheral Sensorimotor Neuropathy |
3.3% |
| Peripheral Sensory Neuropathy |
3.3% |
| Pneumonia |
3.3% |
| Pulmonary Embolism |
3.3% |
|
